The Insider and President & CEO of NeuroMetrix, Inc. (NURO), Shai Gozani, Invested in 5,000 Shares; EASTON PHARMACEUTICA (EAPH) Sellers Increased By 114.56% Their Shorts

The President & CEO of Neurometrix Inc, Shai Gozani is in the stock market news today. It was disclosed in a legal document filled by Shai Gozani and submitted to the Security Exchange Commission on February 5, 2018, she acquired 5,000 shares from the Pinksheet-listed company having a market value near $7,380 US Dollars. The transaction’s shares average price was $1.5. It seems she is very active lately as in the last month, she quietly acquired additional 5,000 shares of the company, worth $8,371 USD. Currently, Mr. Shai, owns 66,196 shares, which accounts for 2.82% of the company’s market cap.

EASTON PHARMACEUTICA (OTCMKTS:EAPH) had an increase of 114.56% in short interest. EAPH’s SI was 56,000 shares in February as released by FINRA. Its up 114.56% from 26,100 shares previously. The stock increased 9.71% or $0.002 during the last trading session, reaching $0.026. About 823,667 shares traded. Easton Pharmaceuticals Inc. (OTCMKTS:EAPH) has 0.00% since February 5, 2017 and is . It has underperformed by 16.70% the S&P500.

Easton Pharmaceuticals Inc., a specialty pharmaceutical company, designs, develops, and markets various topically delivered drugs and therapeutic health care products. The company has market cap of $29.94 million. The Company’s products include Nauseasol, a motion sickness gel; Skin Renou HA, an anti-aging wrinkle cream using hyaluronic acid, which keeps the skin smooth; Kenestrin Gel used for arthritis, knees, elbows, shoulders, wrist, and back pain; Viorra, a hormone free, non-toxic, and topical gel that improves sexual functioning of women; and female sexual arousal disorder drug. It currently has negative earnings. The firm is also developing XILIVE, an early stage cancer drug.

Among 3 analysts covering Neurometrix (NASDAQ:NURO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurometrix has $1600 highest and $1 lowest target. $2.63’s average target is 71.90% above currents $1.53 stock price. Neurometrix had 6 analyst reports since September 1, 2015 according to SRatingsIntel. The stock of NeuroMetrix, Inc. (NASDAQ:NURO) has “Buy” rating given on Friday, October 20 by H.C. Wainwright. H.C. Wainwright maintained the shares of NURO in report on Thursday, June 15 with “Buy” rating. The rating was initiated by Maxim Group on Friday, September 11 with “Buy”. On Tuesday, September 1 the stock rating was upgraded by Zacks to “Hold”. Rodman & Renshaw initiated NeuroMetrix, Inc. (NASDAQ:NURO) rating on Tuesday, June 28. Rodman & Renshaw has “Buy” rating and $4.50 target. The stock has “Buy” rating by H.C. Wainwright on Friday, July 21.

NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company has market cap of $3.59 million. The firm develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. It currently has negative earnings. The Company’s marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; the SENSUS pain therapy device, a prescription neurostimulation device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies.